RG6501 Phase 1/2a Results To Be Featured At Eyecelerator At 2023 American Academy Of Ophthalmology Annual Meeting
Portfolio Pulse from Benzinga Newsdesk
Lineage Cell Therapeutics, Inc. (LCTX) announced that its CEO, Brian M. Culley, will present at the 'Mapping the Future of Geographic Atrophy' session at Eyecelerator 2023. The session will also feature executives from Apellis Pharmaceuticals, Iveric Bio, Annexon Biosciences, Aviceda Therapeutics, and ONL Therapeutics. Additionally, results from a Phase 1/2a clinical study of RG6501 (OpRegen) will be presented, showing evidence of rapid improvement in outer retinal structure and continued clinical benefit. RG6501 is being developed under a collaboration between Lineage, Roche, and Genentech.
October 24, 2023 | 12:16 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Lineage Cell Therapeutics will present at a major conference and share promising results from a clinical study of RG6501, a drug being developed in collaboration with Roche and Genentech.
The announcement of Lineage's participation in a major conference and the presentation of promising clinical results could generate positive sentiment among investors and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100